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Abstract
Background: Patients with severe mental illness are at increased risk for metabolic and
cardiovascular disease. A number of recent guidelines and consensus statements recommend
stringent monitoring of metabolic function in individuals receiving antipsychotic drugs.
Methods: We conducted a prospective cohort study of 106 community-treated psychiatric
patients from across the diagnostic spectrum from the Northeast of England to investigate changes
in metabolic status and monitoring practices for metabolic and cardiovascular disease. We
undertook detailed anthropometric and metabolic assessment at baseline and follow-up, and
examined clinical notes and hospital laboratory records to ascertain monitoring practices.
Results: A high prevalence of undiagnosed and untreated metabolic disease was present at baseline
assessment. Mean follow-up time was 599.3 (SD ± 235.4) days. Body mass index (p < 0.005) and
waist circumference (p < 0.05) had significantly increased at follow-up, as had the number of
individuals who were either overweight or obese. Fifty-three per cent of individuals had
hypertriglyceridemia, and 31% had hypercholesterolemia, but only 7% were receiving lipid-lowering
therapy. Monitoring practices were poor. Recording of measures of adiposity occurred in 0% of
individuals, and > 50% of subjects had neither blood glucose nor lipids monitored during the follow-
up period.
Conclusion: This cohort has a high prevalence of metabolic disease and heightened cardiovascular
risk. Despite the publication of a number of recommendations regarding physical health screening
in this population, monitoring rates are poor, and physical health worsened during the follow-up
period.
Background
Severe mental illness (SMI) is associated with a significant
excess of physical co-morbidity and mortality [1,2], and as
such represents a major public health concern. Previous
studies have reported a high prevalence of undiagnosed
and untreated metabolic disorders and cardiovascular risk
factors in patients with SMI [3-7]. Consensus statements
from the US [8] and UK [9] have recommended stringent
monitoring of metabolic status and cardiovascular risk
factors in psychiatric patients receiving antipsychotic
drugs, and recently published UK guidelines from the
National Institute for Health and Clinical Excellence
(NICE) on the management of schizophrenia [10] and
bipolar disorder [11] recognise the impact of physical co-
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of high-quality research in this field. Currently available
evidence suggests that effective screening and intervention
for metabolic and cardiovascular disease is lacking
[3,4,9,12].
The role of antipsychotic drugs, particularly the second
generation (or atypical) agents, in the pathogenesis of
metabolic dysfunction and CVD in SMI is controversial.
There is a burgeoning literature examining this associa-
tion, and current evidence suggests that some atypical
agents (e.g. clozapine and olanzapine) may have a more
deleterious profile with regard to metabolic dysfunction
than others (e.g. quetiapine and risperidone) [8,9,13].
Notwithstanding the reported association between antip-
sychotic drugs and metabolic dysfunction, prospective,
longitudinal studies investigating the evolution of meta-
bolic disease in this population are sparse. A number of
recent guidelines recommend switching an antipsychotic
drug to an agent with a less deleterious effect on metabolic
function in patients who develop hyperglycaemia or expe-
rience significant weigh gain [8,9,14], but in the absence
of longitudinal data, such strategies lack a firm evidence
base.
We prospectively studied metabolic function in a cohort
of antipsychotic-treated community psychiatric patients
from across the diagnostic spectrum, and investigated
rates of monitoring and intervention for metabolic and
cardiovascular risk.
Methods
We recruited 106 patients from psychiatric out-patient
clinics in the Northeast of England between January 2002
and March 2004. Exclusion criteria and baseline charac-
teristics of this cohort have previously been described [4].
Briefly, the only entry criteria were that the patient was
prescribed an antipsychotic drug (typical, atypical or com-
bination) and was clinically stable. Patients who had ano-
rexia nervosa or bulimia, those who were actively
misusing substances or alcohol, and those with known
malignant disease were excluded. All the secondary care
consultant psychiatrists and primary care physicians
responsible for the mental and physical healthcare of
these patients were sent a detailed summary of the meta-
bolic parameters obtained following the baseline visit,
and any abnormal findings were highlighted. All patients
were invited to participate in this prospective study
between June 2005 and December 2005 as part of a
planned 18-month follow-up assessment. Subjects gave
written informed consent to participate in this study
which was approved by the Newcastle Local Research Eth-
ics Committee.
Participants were given written instructions to fast over-
night on the day before assessment, and subjects were
asked to confirm their fasting status by a member of the
research team on the morning of study. All assessments
were performed between 8.30 am and 10.00 am on the
study day. Demographic and illness characteristics were
recorded, together with family history of type 2 diabetes
and cardiovascular disease. Current medication (includ-
ing non-psychotropic drugs) and dosage was recorded
and confirmed, where necessary, by reference to case
notes and general practitioner records.
Height, weight, and waist and hip circumference were
recorded using standardised anatomical landmarks. A sin-
gle venous blood sample was withdrawn and analysed for
glucose, HbA1c, insulin and lipid profile (total cholesterol,
high-density lipoprotein (HDL-C) and low-density lipo-
protein (LDL-C) cholesterol and triglycerides). Insulin
was measured by ELISA. The homeostatic model assess-
ment [15] was used to assess glucose handling and values
calculated using the HOMA calculator, version 2.2 (© Dia-
betes Trial Unit, University of Oxford). Impaired fasting
glucose (IFG) was defined as fasting blood glucose
between 6.1 and 7.0 mmol/l, and diabetes mellitus as fast-
ing blood glucose > 7.0 mmol/l [16].
All patients' notes were screened for evidence of monitor-
ing of metabolic function and recommendations regard-
ing lifestyle and referrals to other healthcare professionals
during the follow-up period. Hospital biochemistry labo-
ratory records were checked to confirm whether blood
glucose or lipid analyses had been requested by the psy-
chiatrist or a primary care physician, but had not been
recorded in the case-notes.
Data analysis was conducted using the Statistical Package
for the Social Sciences, version 11, [17]. Comparisons
between baseline and follow-up characteristics were
examined by t-test, chi-squared or McNemar tests where
appropriate. All reported p values are two-tailed. Statisti-
cal significance is defined as p < 0.05.
Results
Patient characteristics
Of the original 106 patients in the baseline cohort, 90
(85%) consented to participate in the current study. Six
(5.7%) did not reply to the invitation, 6 (5.7%) refused to
consent, 2 (1.9%) were too unwell to participate, and 1
patient (1%) denied having participated in the original
study. Baseline and follow-up characteristics of the 90
patients are given in table 1. Forty-four (49%) of subjects
were male and 46 (51%) were female. Eighty-eight (98%)
were Caucasian. With regard to diagnosis, 32 (35.6%) had
bipolar disorder, 27 (30.0%) had schizophrenia, 9
(10.0%) had schizo-affective disorder, and 22 (24.4%)Page 2 of 6
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between the baseline and follow-up visits was 599.3 days
(SD ± 235.4; Range 328–1175). Of note is the high prev-
alence of family history of both cardiovascular disease
and diabetes mellitus in the first-degree relatives of sub-
jects.
Medication
Of the 90 patients prescribed antipsychotic medication at
baseline, 83 (92%) were still taking an antipsychotic drug
at follow-up. Sixty-eight (82%) patients were prescribed
the same antipsychotic regimen as at baseline assessment.
Details of individual drugs are given in table 2.
Metabolic parameters
Comparisons between baseline and follow-up metabolic
parameters are given in table 3. Both BMI and waist cir-
cumference were significantly increased at follow-up, and
a greater proportion of subjects were classified as over-
weight (BMI ≥ 25 kg/m2) compared with follow-up. In the
whole cohort, pancreatic β-cell function and insulin
resistance estimated by HOMA were significantly lower at
follow-up compared with baseline, but these parameters
were not significantly different when those subjects no
longer prescribed antipsychotic drugs (n = 7) were
removed from the analysis. A high proportion of patients
had dyslipidaemias at baseline (hypercholesterolemia =
27.8%; hypertriglyceridemia = 53.3%), and continued to
do so at follow-up (hypercholesterolemia = 28.9%; hyper-
triglyceridemia = 51.1%). At follow-up, 30 patients
(33.3%) met criteria for the metabolic syndrome as
defined by the International Diabetes Federation [18]. A
comparison between rates of metabolic syndrome at base-
line and follow-up was not possible as blood pressure
readings were not available from the baseline assessment.
Prescribing rates of lipid-lowering therapies were low
(4.4% and 7.8% at baseline and follow-up, respectively).
Monitoring
Details of records in the case notes of BMI, identified
weight problems and referrals to other health care profes-
sionals for lifestyle or medical intervention are given in
table 4, along with the proportion of subjects who
received blood glucose and/or lipid monitoring during
the follow-up period. Monitoring of metabolic status was
poor across all domains, the majority of patients receiving
no assessment of metabolic function (BMI, waist circum-
ference, blood glucose or lipid measurement) during the
follow-up period.
Table 2: Antipsychotic, and non-antipsychotic medication taken 
by patients with SMI
Drug n (%)
Antipsychotic (n = 90)
Yes 83 (92.2)
No 7 (7.8)
One antipsychotic 71 (78.8)
Combination antipsychotic 12 (13.3)
Typical or atypical agent (n = 71)
Typical 16 (22.5)
Zuclopenthixol 2 (2.8)
Flupenthixol 5 (7.0)
Haloperidol 1 (1.4)
Fluphenazine 1 (1.4)
Pipothiazine 1 (1.4)
Sulpiride 4 (5.6)
Trifluoperazine 2 (2.8)
Atypical 55 (77.5)
Amisulpiride 3 (4.2)
Clozapine 7 (9.9)
Olanzapine 29 (40.8)
Quetiapine 8 (11.3)
Risperidone 8 (11.3)
Non-antipsychotic psychotropic drugs (n = 90)
Antidepressants
SSRI 29 (32.2)
SNRI 9 (10)
NaSSA 4 (4.4)
TCA 7 (7.8)
MAOI 3 (3.3)
Mood Stabiliser
Valproate 16 (17.8)
Lamotrigine 8 (8.9)
Carbamazepine 1 (1.1)
Lithium 15 (16.7)
Other
Gabapentin 2 (2.2)
Benzodiazepines 28 (31.1)
Tryptophan 2 (2.2)
Anticholinergic agent 15 (16.7)
Non-psychotropic drugs (n = 90)
Antihypertensive agent 13 (14.4)
Thyroxine 10 (11.1)
Hypoglycaemic agent 4 (4.4)
Table 1: Characteristics of 90 patients at baseline and follow-up 
assessment.
Baseline Follow-up
(n = 90) (n = 90)
Age, years 44.2 (11.7) 45.8 (11.8)
Duration of illness, months 212.6 (154.8) 230.6 (161.2)
Smoking, % 40 40
Cigarettes n/day 12.1 (15.5) 10.7 (15.9)
Alcohol units/day 5.6 (9.2) 6.8 (12.3)
Current substance misuse (%) 32.2 30
Family history of DM (%) 30.0 34.4
Family history of CVD (%) 58.9 61.0
DM – Diabetes mellitus; CVD – cardiovascular disease
Data are means ± SD unless otherwise statedPage 3 of 6
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At baseline there was a high prevalence of overweight,
obesity and dyslipidaemias in this population; a signifi-
cant proportion of patients also had undiagnosed disor-
ders of glucose homeostasis, and treatment rates for these
metabolic disorders was low [4]. Despite informing indi-
vidual primary and secondary care physicians of these
baseline results, after a mean follow-up period of 19.2
months, the metabolic parameters of this cohort had
either worsened or remained unchanged.
Mean BMI had significantly increased during the follow-
up period, as had the number of individuals who were in
the overweight or obese categories. Waist circumference, a
measure of visceral adiposity closely associated with Type
2 diabetes [19] and cardiovascular risk [20], had also sig-
nificantly increased compared with baseline values. A
high proportion of patients had elevated total cholesterol
and/or triglycerides at baseline assessment, and a similar
proportion had dyslipidaemias at follow-up assessment.
More than 50% of individuals had raised triglycerides,
and almost 30% had elevated total cholesterol at follow-
up, but only 7% were prescribed lipid-lowering therapy,
which was marginally increased from 4% at baseline.
Taken together, these data suggest that the metabolic sta-
tus of this cohort of patients, all of whom are in contact
with mental health services, is worsening over time, and
appropriate intervention appears to be lacking. Given the
established increased risk of cardiovascular morbidity and
mortality in individuals with severe mental illness [21],
this is a worrying and ominous trend.
The metabolic health of these patients and poor rates of
intervention may be explained, at least in part, by inade-
quate monitoring practices. A number of recent guidelines
and consensus documents have highlighted the need for
close monitoring of metabolic function in this population
in order to minimise cardiovascular risk [9-11]. Regular
monitoring of measures of adiposity and serum glucose
and lipid estimation is recommended by all these docu-
ments.
Our data reveal an alarmingly poor rate of monitoring of
metabolic parameters; BMI or waist circumference was
not recorded in the psychiatric case notes of any patient.
Although the presence of a weight-problem was identified
in 21% of patients there was documented evidence of life-
style advice in less than 10%, and only 7% were referred
to another healthcare professional for further interven-
tion. Monitoring of blood glucose and lipid levels was
Table 3: Comparison of baseline and follow-up metabolic parameters.
Baseline Follow-up Follow-up
(n = 90) (all subjects, n = 90) (antipsychotic-treated subjects, n = 83)
BMI, kg/m2 29.2 (5.1) 29.9 (4.9)* 29.8 (4.9)*
BMI category 
Underweight (%) 1.1 2.2 2.4
Normal (%) 16.7 10.0 8.4
Overweight (%) 34.4 43.3* 44.6*
Obese (%) 47.8 44.4 44.6
Waist Circumference, cm 94.6 (13.2) 96.2 (13.1) † 96.2 (13.0) †
Fasting blood glucose, mmol/l 5.6 (2.4) 5.5 (1.4) 5.5 (1.4)
HbA1c, % 5.4 (1.2) 5.6 (1.0) 5.6 (1.0)
Serum insulin, MU/l 12.9 (13.4) 11.1 (8.1) 11.1 (8.2)
HOMA B, % 106.3 (38.6) 98.8 (38.8) † 99.7 (39.7)
HOMA S, % 95.9 (60.5) 98.6 (55.6) 98.4 (55.6)
HOMA IR, % 1.8 (1.7) 1.5 (1.1) † 1.5 (1.1)
Glycaemic status
Normoglycaemia, % 86.7 85.6 86.8
Impaired fasting glucose, % 6.7 8.9 7.2
Diabetes Mellitus, % 6.7 5.6 6.0
Total Cholesterol, mmol/l 5.6 (1.2) 5.7 (1.5) 5.7 (1.5)
Raised total cholesterol, % 27.8 28.9 31.3
HDL-Cholesterol, mmol/l 1.3 (0.4) 1.3 (0.4) 1.3 (0.4)
LDL-Cholesterol, mmol/l 3.2 (0.9) 3.3 (1.1) 3.3 (1.3)
Triglycerides, mean (range), mmol/l 2.3 (0.6–8.4) 2.1 (0.5–6.9) 2.1 (0.5–6.9)
Raised total triglycerides, % 53.3 51.1 53.0
Lipid-lowering therapy, % 4.4 7.8 7.2
* p < 0.005 baseline vs follow-up; † p < 0.05 baseline vs follow-up
Data are means ± SD unless otherwise stated.Page 4 of 6
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received blood glucose or lipid monitoring during the fol-
low-up period; only 27% of individuals had received both
glucose and lipid monitoring. Where glucose and lipid
monitoring had been performed, for the majority of
patients this had not taken place within the preceding 12
months. Although we were able to establish the propor-
tion of patients who had undergone blood monitoring
during the follow-up period from hospital laboratory
databases, the vast majority of these results (> 90%) were
not recorded in the psychiatric case notes indicating that
psychiatrists were unaware of the metabolic status of these
individuals.
Another observation of interest is the high reported prev-
alence of a positive family history of both type 2 diabetes
(34%) and cardiovascular disease (61%) in the first
degree relatives of subjects. The high prevalence of type 2
diabetes (18–30%) in mentally well first-degree relatives
of individuals with schizophrenia has previously been
reported [22], leading to speculation that there may be
common susceptibility regions within the genome for
both schizophrenia and type 2 diabetes [23]. Shared expo-
sure to environmental influences known to be involved in
the pathogenesis of diabetes may also partly explain this
relationship. We are not aware of any previous data
reporting a high prevalence of cardiovascular disease in
first degree relatives of patients with severe mental illness.
The prevalence of type 2 diabetes in relatives together with
other shared genetic and environmental influences may
explain this association, but this is an area of investigation
which warrants further research.
This study has a number of limitations. Subjects were
recruited from secondary and tertiary care mental health
outpatient clinics, and all volunteered to participate. This
cohort is, therefore, likely to comprise a group of relatively
well motivated individuals who may take a more active
interest in their physical (and mental) well-being than
those individuals who were not in contact with mental
health services or who refused to participate in this study.
The physical health of this cohort may, therefore, not be
representative of all psychiatric out-patients. In fact, it is
probable that the physical health of those individuals
who are not in contact with mental health services or who
refuse to participate in physical health screening studies is
less closely monitored, and therefore this population will
have an even greater burden of physical co-morbidity and
cardiovascular risk. The fact that subjects were recruited
from a single well-defined geographical region within the
UK may raise questions about extrapolating these data to
other populations. However, primary and secondary care
health service configurations within this geographical
region are typical for the UK, and subjects were recruited
from a number of community mental health centres rep-
resenting a diverse socioeconomic population. A further
limitation of this study is the lack of data on specific drug-
effects on metabolic function. This study was not
designed, nor indeed powered, to investigate the effects of
individual antipsychotic drugs, or classes of drugs, on the
evolution of metabolic dysfunction; our aim was to inves-
tigate monitoring practices for metabolic and cardiovas-
cular risk and to describe the change over time of
metabolic function in a diagnostically diverse cohort of
patients treated with any antipsychotic drug.
Conclusion
In summary, we have presented data from a prospective
study on monitoring practices for metabolic function in a
cohort of antipsychotic-treated outpatients with severe
mental illness from across the diagnostic spectrum. At
baseline assessment there was a high prevalence of over-
weight, obesity and dyslipidaemias. Despite notifying rel-
evant healthcare professionals about the extent of
physical morbidity in this population, and the existence
of a number of recently published guidelines and recom-
mendations on physical health monitoring in patients
receiving antipsychotic drugs, metabolic parameters were
either unchanged or, in some cases, significantly worse, at
follow-up assessment. Rates of monitoring of measures of
Table 4: Monitoring of metabolic parameters in 90 patients over 
an 18-month follow-up period.
Number of patients 
monitored
(%)
BMI
Yes 0
No 100
Waist circumference
Yes 0
No 100
Weight problem identified
Yes 21.6
No 78.4
Lifestyle advice offered
Yes 9.5
No 90.5
Referral to health care professional 
Practice nurse 4.0
Dietician 1.3
Other physician 1.3
None 93.3
Blood monitoring
Glucose and lipids 26.7
Glucose only 13.3
Lipids only 8.9
Neither 51.1
> 12 months since monitoring
Glucose 67.8
Lipids 72.2Page 5 of 6
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healthcare professionals for medical or lifestyle interven-
tion, and treatment for metabolic diseases is poor, and in
many cases non-existent. There is a clear and urgent need
to develop integrated models of care which specifically
target the physical health of this population which already
suffers an excess burden of physical morbidity and mor-
tality.
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